ELANNYSEPharmaceutical PreparationsFiscal year ends December 31
Elanco Animal Health Inc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$23.49−0.06 (-0.25%)
Close on Oct 19, 2026
- Market cap
- $11.88B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$2.07 (+9.66%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Elanco Animal Health Inc grew revenue 12.0% to $5.02B over the twelve months to Jun 30, 2026. Free cash flow was $379.00M, up 5.0% from a year earlier.
Revenue
$5.02B
+12.0% vs. a year earlier
Free cash flow
$379.00M
+5.0% vs. a year earlier
EPS, diluted
-$0.42
-148.8% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $11.88B
- P/E ratio
- –
- Price to sales
- 2.37
- Price to book
- 1.80
- Dividend yield
- –
- Free cash flow yield
- 3.19%
Fundamentals
- Revenue
- $5.02B
- Net income
- -$199.00M
- EPS, diluted
- -$0.42
- Free cash flow
- $379.00M
- Book value per share
- $13.02
- Diluted shares
- 506M
Eleven years at a glance
Fiscal years 2015 to 2025 and trailing twelve months, USD
Revenue
$5.02B+12.0% YoY
Gross profit
$2.78B+13.2% YoY
Net income
-$199.00M-145.9% YoY
EPS, diluted
-$0.42-148.8% YoY
Free cash flow
$379.00M+5.0% YoY
Reported periodTrailing twelve months